Xilio To Present Initial Data From Its Ongoing Phase 2 Trial For Vilastobart At ASCO GI; Reports Preliminary Phase 1 Data For XTX301 Showing Improved Tolerability Profile Over Historical Data For RhIL-12
Xilio To Present Initial Data From Its Ongoing Phase 2 Trial For Vilastobart At ASCO GI; Reports Preliminary Phase 1 Data For XTX301 Showing Improved Tolerability Profile Over Historical Data For RhIL-12
"We are encouraged by the early evidence of responses in patients with cold tumors, including MSS colorectal cancer, reported for the combination of vilastobart and atezolizumab in Phase 1C dose escalation earlier this year, and we look forward to sharing initial Phase 2 data for the combination in MSS CRC at ASCO GI in January," said Katarina Luptakova, M.D., chief medical officer of Xilio.
「我們對早期數據顯示，對於冷腫瘤患者，包括MSS結直腸癌，在今年早些時候進行的1C期劑量遞增研究中，vilastobart與atezolizumab的聯合療法表現出反應感到鼓舞，期待在1月的ASCO GI會議上分享MSS CRC聯合療法的初步2期數據，」Xilio的首席醫療官Katarina Luptakova萬.D.說。
"In addition, the preliminary Phase 1 data we reported today for XTX301, our tumor-activated IL-12, highlight its promising clinical profile, including no dose-limiting toxicities reported to date and consistent interferon gamma signaling observed throughout treatment cycles."
「此外，我們今天報告的XTX301（我們腫瘤激活的IL-12）的初步1期數據突出了其良好的臨床特徵，包括迄今爲止沒有報告的劑量限制性毒性，並且治療週期中觀察到一致的干擾素gamma信號。」
譯文內容由第三人軟體翻譯。
